Currently, the therapy of BC patients is mainly dictated by well-established biological biomarkers, including estrogen receptors (ER), progesterone receptors (PR), HER2, and the Ki-67 proliferation index, together with TNM staging and age. This evidence concerns the gene PGR and breast cancer.